Peripheral Neuropathy Due to Chemotherapy Clinical Trial
Official title:
Efficacy of Losartan in the Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients.
Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, leading to treatment failure. A lot of interventions have been tried to prevent PIPN, ensure complete administration of the chemotherapy cycles, and increase the survival rate. One of the promising interventions in the prevention of PIPN is Losartan. Losartan is an angiotensin receptor blocker (ARBs) and is used to treat hypertensive patients. There is strong evidence from different preclinical studies and retrospective cohort studies that Losartan has a neuroprotective effect. The purpose of our study is to investigate the efficacy of Losartan in the prevention of peripheral neuropathy associated with Paclitaxel treatment in Breast Cancer patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05875610 -
Preventive Approach Using Venlafaxine
|
Phase 4 | |
| Not yet recruiting |
NCT06313359 -
Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.
|
||
| Not yet recruiting |
NCT06459193 -
Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03571334 -
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
|
Phase 2 | |
| Completed |
NCT04461977 -
Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer
|
N/A | |
| Completed |
NCT03492047 -
N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients
|
Phase 1/Phase 2 |